secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvectis Pharma, Inc. (NVCT)
CIK:        0001875558
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001104659-24-086127
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvectis Q2 2024 net loss narrows to $4.4M; progressing NXP800 and NXP900 trials
--------------------------------------------------------------------------------

- Cash $18.1M at June 30, 2024, down $1.4M from March 31, 2024; net loss $4.4M vs $5.8M YoY.
- R&D spend $2.9M (-33% YoY); G&A $1.7M (+13%); interest income $0.2M.
- NXP800 Phase 1b ovarian cancer trial enrolling at ~15 US/UK sites; update due fall 2024.
- NXP800 investigator-sponsored cholangiocarcinoma trial recruiting; update expected by end of 2024.
- NXP900 dose escalation: 3 cohorts complete, no DLTs; planning combo with EGFR/ALK inhibitors in NSCLC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1875558/000110465924086127/0001104659-24-086127-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1875558/000110465924086127/tm2420911d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-086127

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer